Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 34021 FU2 in Healthy Males
NCT02259842Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 34021 (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of participants with clinically significant findings on physical examination, Number of participants with clinically significant findings in vital signs and 4 more. Started Mar 2008; status: completed.
02
Drugs
BI 34021
Beyond the preview
Go deeper on NCT02259842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259842.